Comparison tool

Epithalon vs Cartalax side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

EpithalonCartalax

Share this peptide comparison

Property	Epithalon	Cartalax
Category	Bioregulators	Bioregulators
Also known as	Epitalon, Epithalone, AGAG	Ala-Glu-Asp, AED Tripeptide
FDA approved	No	No
Clinical status	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Available in Russia; not FDA approved Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Longevity, telomere support, anti-aging, sleep	Joint health, cartilage support, osteoarthritis
How it works	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.	Cartalax is presented as AED, a short cytogen peptide for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related preclinical work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.
Typical dosing	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days	Limited community data available · See research protocols
Research dosing	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection	10-20 mg daily · 10-30 day courses · Oral
Typical duration	10-20 day cycles	10-30 day courses
Administration	Subcutaneous or intramuscular injection	Oral
Timing	Before bed With or without food	Morning or as directed With or without food
Evidence level	Clinical Trials	Preclinical
Possible side effects	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 more Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)	Generally well-tolerated (Reported by the source, but safety documentation is limited.) Mild injection site reactions (Listed as a mild reported effect.) Transient fatigue (Listed as a reported transient effect.) +2 more Mild gastrointestinal upset (Described by the source as rare.) Limited documented side-effect data (The source indicates that adverse-effect reporting is incomplete.)
Research summary	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.	The supplied research summary places Cartalax in a preclinical evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.
References	PubMed PubMed +2 more WikipediaEpitalon Springer	Peptibase peptides Peptibase peptides +1 more Peptibase peptides
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Epithalon

Cartalax

Category

Bioregulators

Also known as

Epitalon, Epithalone, AGAG

Ala-Glu-Asp, AED Tripeptide

FDA approved

Clinical status

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Available in Russia; not FDA approved

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Longevity, telomere support, anti-aging, sleep

Joint health, cartilage support, osteoarthritis

How it works

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Cartalax is presented as AED, a short cytogen peptide for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related preclinical work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.

Typical dosing

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Limited community data available · See research protocols

Research dosing

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

10-20 mg daily · 10-30 day courses · Oral

Typical duration

10-20 day cycles

10-30 day courses

Administration

Subcutaneous or intramuscular injection

Oral

Timing

Before bed

With or without food

Morning or as directed

With or without food

Evidence level

Clinical Trials

Preclinical

Possible side effects

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 more

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Generally well-tolerated (Reported by the source, but safety documentation is limited.)
Mild injection site reactions (Listed as a mild reported effect.)
Transient fatigue (Listed as a reported transient effect.)

+2 more

Mild gastrointestinal upset (Described by the source as rare.)
Limited documented side-effect data (The source indicates that adverse-effect reporting is incomplete.)

Research summary

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

The supplied research summary places Cartalax in a preclinical evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.

References

PubMed PubMed

+2 more

WikipediaEpitalon Springer

Peptibase peptides Peptibase peptides

+1 more

Peptibase peptides

Full profile

View Details